The Journal of Antibiotics · 1983 · 103 citations · 9 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryOncology PharmacologyStructure-activity Relationship AnalysisAnticancer ActivityAnticancer Natural Products
CI-920 (PD 110,161) and two analogues (PD 113,270 and PD 113,271) are novel antitumor compounds produced by a new actinomycete characterized as Streptomyces pulveraceus subsp. fostreus ATCC 31906. The antitumor compounds are predominantly produced during the stationary (idiophase) growth phase of the organism. CI-920 is active versus the murine P388 lymphocytic and L1210 lymphoid leukemia with T/C values of 246 and 207, respectively. This compound has no significant antimicrobial activity.
9
Bergey's Manual of Determinative Bacteriology
F. A. S., R. E. Buchanan, N. E. Gibbons et al. · Taxon · 1975 · 11.4K citations